DARATUMUMAB, DEXAMETHASONE, POMALIDOMIDE, DEXAMETHASONE, POMALIDOMIDE, POMALIDOMIDE, Surzetoclax, Surzetoclax, DEXAMETHASONE
M25-275
Phase 2 small_molecule active
Quick answer
DARATUMUMAB, DEXAMETHASONE, POMALIDOMIDE, DEXAMETHASONE, POMALIDOMIDE, POMALIDOMIDE, Surzetoclax, Surzetoclax, DEXAMETHASONE for Multiple Myeloma (MM). is a Phase 2 program (small_molecule) at AbbVie Deutschland GmbH & Co. KG with 1 ClinicalTrials.gov record(s).
Program details
- Company
- AbbVie Deutschland GmbH & Co. KG
- Indication
- Multiple Myeloma (MM).
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active